ARTICLE SUMMARY:
In a large and growing class of tech companies operating in decentralized clinical trials, Hawthorne Effect differentiates itself with a heritage based on the complexities of medtech, and an Uber-like model that comes to the patient.
In 2021, funding for companies in a relatively new category known as decentralized clinical trials (DCTs) has been plentiful. These businesses are developing models to streamline clinical trial workflow with technologies that connect study subjects, from whom data needs to be routinely gathered, to investigators. Since January, several companies, including Science 37, Curebase Inc., HumanFirst, Castor, Antidote Technologies Ltd., ObvioHealth USA Inc., and Hawthorne Effect have completed financing rounds raising double-digit sums. Upping the ante, Medable Inc. raised a $304 million Series D round in October, valuing the company at $2.1 billion.
